Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced new distribution partnerships for its ViroCAP® product in Spain, Portugal, Greece, the Balkan region, Romania, and Saudi Arabia. The agreements, each with a separate company for individual markets, are set to significantly expand the company's international presence and are expected to generate additional sales of at least 3,000 devices per year.
ViroCAP® is a mobile medical device designed for the treatment of skin conditions using cold atmospheric plasma. It is intended for use by hospitals, physicians in private practice, and surgically active medical specialists. The device has been a key product for Viromed, which has been listed on the stock exchange since October 2022 and operates through its wholly owned subsidiary, Viromed Medical GmbH.
Uwe Perbandt, Chief Executive Officer of Viromed Medical AG, commented on the expansion: “With these new distribution partners, we are opening up several attractive markets in Southern and South-Eastern Europe as well as in the Middle East. The strong interest shown by our distribution partners underlines the high demand for our cold plasma technology. The new distribution partnerships are another important step in the implementation of our dynamic growth phase. Partnerships for additional countries are in preparation and are expected to be signed within the next four to six weeks.”
This move builds on Viromed's existing distribution network, which already includes an exclusive agreement with South Korea's UMECO covering ten Asian countries and a partnership with TriPart TITAN GmbH & Co. KG for the Turkish market. The company's focus on expanding its reach aligns with its goal of advancing the use of cold plasma technology in medicine and capitalizing on growth opportunities.
The new agreements are part of Viromed's broader strategy to penetrate diverse geographic markets. By securing minimum purchase quantities in each partnership, the company ensures a baseline revenue stream, which is crucial for its growth phase. The addition of these six markets not only diversifies Viromed's revenue sources but also enhances its brand presence in regions with growing healthcare demands.
For industry observers, this expansion signals a growing acceptance of cold plasma technology in medical treatments. As Viromed continues to forge partnerships, the company is positioning itself as a leader in this niche field, potentially influencing how skin conditions are treated globally. The expected signing of additional partnerships within the next few weeks suggests that Viromed's momentum is likely to continue, further solidifying its market position.
Viromed Medical AG's commitment to innovation and international growth is evident in these strategic moves. By leveraging its technology and expanding its distribution channels, the company is well-placed to meet the rising demand for advanced medical devices. The new partnerships are a testament to the company's ability to attract reliable partners and to the viability of its product in various healthcare settings.
As the company moves forward, the impact of these agreements will be watched closely by stakeholders and competitors alike. With a clear focus on growth and a robust distribution strategy, Viromed is set to make significant strides in the medical technology sector.
